- Home
- WNS vs MRUS Comparison
WNS vs MRUS Comparison
Compare WNS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNS
- MRUS
- Stock Information
- Founded
- WNS 1996
- MRUS 2003
- Country
- WNS India
- MRUS Netherlands
- Employees
- WNS N/A
- MRUS N/A
- Industry
- WNS Business Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- WNS Consumer Discretionary
- MRUS Health Care
- Exchange
- WNS Nasdaq
- MRUS Nasdaq
- Market Cap
- WNS 2.6B
- MRUS 2.8B
- IPO Year
- WNS N/A
- MRUS 2016
- Fundamental
- Price
- WNS $55.47
- MRUS $47.37
- Analyst Decision
- WNS Buy
- MRUS Strong Buy
- Analyst Count
- WNS 9
- MRUS 13
- Target Price
- WNS $61.00
- MRUS $85.67
- AVG Volume (30 Days)
- WNS 484.9K
- MRUS 513.2K
- Earning Date
- WNS 01-23-2025
- MRUS 02-26-2025
- Dividend Yield
- WNS N/A
- MRUS N/A
- EPS Growth
- WNS N/A
- MRUS N/A
- EPS
- WNS 2.70
- MRUS N/A
- Revenue
- WNS $1,315,456,000.00
- MRUS $35,932,000.00
- Revenue This Year
- WNS N/A
- MRUS N/A
- Revenue Next Year
- WNS $6.96
- MRUS $42.15
- P/E Ratio
- WNS $21.37
- MRUS N/A
- Revenue Growth
- WNS 1.07
- MRUS N/A
- 52 Week Low
- WNS $39.85
- MRUS $37.77
- 52 Week High
- WNS $65.03
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- WNS 45.71
- MRUS 71.36
- Support Level
- WNS $57.42
- MRUS $39.67
- Resistance Level
- WNS $59.00
- MRUS $41.15
- Average True Range (ATR)
- WNS 1.66
- MRUS 1.71
- MACD
- WNS -0.83
- MRUS 0.86
- Stochastic Oscillator
- WNS 3.32
- MRUS 91.57
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.